Four months after restructuring the ailing Aegerion and axing about 80 staffers, CEO Mary Szela has completed the deal she wanted to bring in a late-stage asset.
Aegerion announced this morning that it will merge with Vancouver-based QLT, creating a new biotech named Novelion that leaves the QLT shareholders with the lion’s share of the stock and Szela with the helm.
An investment syndicate led by Deerfield is also stepping in to inject $22 million into the company through a share purchase agreement. And QLT’s investors will wind up with 67% of the shares of Novelion.
Shares of Aegerion shot up 42% on Wednesday morning.
Aegerion was afflicted by a variety of troubles. Ex-CEO Marc Beer ran into a hornet’s nest of regulatory issues, accused of making unsubstantiated claims about its drug Juxtapid. The drug, meanwhile, fell far short of expectations on the market, and Beer’s messy divorce added a few salacious allegations that helped set the stage for activist investor Alex Denner to push for a change.
That change became Szela, who had left Melinta earlier.
“A late-stage agent would be particularly impactful,” Szela told me earlier in the year as she sought to right a listing ship.
That asset materialized in QLT’s zuretinol (QLT091001) which the companies describe as a Phase III-ready orphan drug targeting inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes, spotlighting Leber Congenital Amaurosis and Retinitis Pigmentosa.
QLT, meanwhile, has experienced its own turmoil. The Canadian biotech has announced and called off two earlier mergers, including a recent pact with Auxilium.
Now Szela will see if she can make one good biotech out of two troubled companies, with its HQ in Canada and its operations in Cambridge, MA. It’s a sizable task.
By John Carroll
Source: Fierce Biotech
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”